HLB Life Science Co., Ltd. (067630.KQ)
KRW 9780.0
(-1.81%)
KRW 9780.0
(-1.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.79 Billion KRW | -18.94% |
| 2022 | -48.59 Billion KRW | 7.88% |
| 2021 | -53.87 Billion KRW | -151.86% |
| 2020 | -45.2 Billion KRW | -85.77% |
| 2019 | 18.09 Billion KRW | 53.15% |
| 2018 | -9.27 Billion KRW | -1073.21% |
| 2017 | 9.69 Billion KRW | 195.73% |
| 2016 | 393.32 Million KRW | 91.89% |
| 2015 | -14.29 Billion KRW | -577.52% |
| 2014 | 2.05 Billion KRW | 175.29% |
| 2013 | -1.68 Billion KRW | 30.73% |
| 2012 | -5.67 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.75 Billion KRW | -17.55% |
| 2024 Q1 | -4.04 Billion KRW | 48.52% |
| 2023 Q2 | -4.6 Billion KRW | -394.29% |
| 2023 Q4 | -6.9 Billion KRW | -53.72% |
| 2023 Q3 | -4.49 Billion KRW | 2.42% |
| 2023 FY | - KRW | -18.94% |
| 2023 Q1 | -931.04 Million KRW | 85.57% |
| 2022 Q2 | -4.09 Billion KRW | -818.37% |
| 2022 Q4 | -6.45 Billion KRW | -71.85% |
| 2022 Q3 | -3.75 Billion KRW | 8.24% |
| 2022 FY | - KRW | 7.88% |
| 2022 Q1 | -445.54 Million KRW | 95.14% |
| 2021 Q2 | -2.87 Billion KRW | -39.88% |
| 2021 Q4 | -9.17 Billion KRW | -421.08% |
| 2021 Q1 | -2.05 Billion KRW | -59.8% |
| 2021 Q3 | -1.76 Billion KRW | 38.8% |
| 2021 FY | - KRW | -151.86% |
| 2020 Q2 | -1.03 Billion KRW | 53.12% |
| 2020 FY | - KRW | -85.77% |
| 2020 Q4 | -1.28 Billion KRW | 8.09% |
| 2020 Q3 | -1.4 Billion KRW | -35.9% |
| 2020 Q1 | -2.19 Billion KRW | -172.47% |
| 2019 Q3 | -4.41 Billion KRW | -126.24% |
| 2019 Q2 | -1.95 Billion KRW | -102.86% |
| 2019 Q1 | -961.56 Million KRW | 65.15% |
| 2019 FY | - KRW | 53.15% |
| 2019 Q4 | 3.03 Billion KRW | 168.72% |
| 2018 Q4 | -2.75 Billion KRW | -67.22% |
| 2018 Q3 | -1.64 Billion KRW | 9.71% |
| 2018 Q2 | -1.82 Billion KRW | -49.76% |
| 2018 Q1 | -1.22 Billion KRW | -262.91% |
| 2018 FY | - KRW | -1073.21% |
| 2017 Q1 | -151.19 Million KRW | -114.57% |
| 2017 Q3 | -162.02 Million KRW | -141.14% |
| 2017 Q4 | 749.03 Million KRW | 562.31% |
| 2017 Q2 | 393.84 Million KRW | 360.48% |
| 2017 FY | - KRW | 195.73% |
| 2016 Q3 | -1.33 Billion KRW | -216.84% |
| 2016 Q4 | 1.03 Billion KRW | 177.79% |
| 2016 FY | - KRW | 91.89% |
| 2016 Q2 | -421.14 Million KRW | -135.71% |
| 2016 Q1 | -178.66 Million KRW | 91.69% |
| 2015 Q1 | -1.35 Billion KRW | -201.82% |
| 2015 Q2 | -4.48 Billion KRW | -231.97% |
| 2015 Q4 | -2.15 Billion KRW | -12.12% |
| 2015 Q3 | -1.91 Billion KRW | 57.22% |
| 2015 FY | - KRW | -577.52% |
| 2014 Q1 | -36.93 Million KRW | 97.76% |
| 2014 Q2 | 334.24 Million KRW | 1004.9% |
| 2014 FY | - KRW | 175.29% |
| 2014 Q3 | 256.87 Million KRW | -23.15% |
| 2014 Q4 | 1.32 Billion KRW | 416.44% |
| 2013 Q2 | -549.51 Million KRW | -13.15% |
| 2013 Q3 | -46.77 Million KRW | 91.49% |
| 2013 Q4 | -1.64 Billion KRW | -3426.39% |
| 2013 FY | - KRW | 30.73% |
| 2013 Q1 | -485.65 Million KRW | 79.81% |
| 2012 Q3 | -843.85 Million KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | -2.4 Billion KRW | -185.12% |
| Name | EBITDA | EBITDA Difference |
|---|